Introduction {#s1}
============

During the development of an organism, tissues are sculpted into different three-dimensional forms. Cell shape changes and cell movements drive these tissue-scale transformations. The molecular motor non-muscle myosin II (myosin) is thought to be important for many of these events; however, the underlying mechanism is not understood.

Myosin is a hexamer composed of two myosin heavy chains, two regulatory light chains (RLCs), and two essential light chains (ELCs) ([Figure 1A](#fig1){ref-type="fig"}). The motor domain at the N-terminus of the myosin heavy chain binds actin filaments in an ATP-dependent manner. The motor domain catalyzes the hydrolysis of ATP to power the translocation of actin filaments, a function referred to as motor activity. The light chains bind to the central neck domain of the myosin heavy chain and have structural and regulatory functions ([@bib21]). The C-terminal tail of the myosin heavy chain associates with the tails of other myosin heavy chains and promotes the assembly into bipolar filaments. Work done using smooth muscle myosin and mammalian non-muscle myosin have demonstrated that phosphorylation of the RLC at conserved Serine and Threonine sites ([Figure 1B](#fig1){ref-type="fig"}, Serine-19 and Threonine-18) activates myosin motor activity, enhances the affinity of myosin for actin, and promotes myosin filament assembly ([@bib23]). The bipolar myosin filaments promote the sliding of antiparallel actin filaments relative to one another resulting in contraction of an actin network. Myosin light chain kinase (MLCK), Rho-associated protein kinase (ROCK), and Citron kinase are known to activate myosin through direct phosphorylation of the RLC, primarily on Serine-19 ([@bib2]; [@bib21]; [@bib45]; [@bib66]). In *Drosophila*, the importance of myosin light chain phosphorylation has been shown through genetic studies ([@bib28]; [@bib36]; [@bib41]; [@bib44]; [@bib63]). However, it has not been biochemically demonstrated that *Drosophila* myosin motor activity and filament assembly is regulated by RLC phosphorylation or whether the extent of activation is similar to that of mammalian systems.10.7554/eLife.20828.002Figure 1.Biochemical characterization of RLC-TS and RLC mutants.(**A**) Domain organization of the myosin heavy chain and myosin fragments used to study the biochemical properties of myosin. The top panel shows the myosin hexamer composed of two myosin heavy chains (green), two ELCs (light blue) and two RLCs (gray). The myosin motor domain, the light chain binding neck and the tail domain of the heavy chain are indicated. The bottom panel shows the double headed HMM fragment. The rational for the different myosin fragments lies in the different biochemical properties: Full-length myosin forms filaments, sediments at high speed and can be used in the in vitro motility assay. The HMM fragment is soluble under physiological salt concentrations and suitable to study kinetic properties, the interaction with actin, and regulatory properties including RLC phosphorylation. (**B**) Multiple sequence alignment of RLCs from different model organisms and RLC mutants. (Top) Sequence alignment showing the high degree of conservation between RLCs from different model organisms. Identical amino acids are colored brown. The primary phosphorylation site of MLCK corresponds to Serine-21 (orange), the secondary phosphorylation site to Threonine-20 (yellow) of the *Drosophila* RLC. (Bottom) Alignment showing the mutant RLCs used in this study and the respective amino acid substitutions at the sites corresponding to Threonine-20 and Serine-21 of the *Drosophila* RLC. Alanine replacements are shown in blue, Glutamate replacements in red. Alanine replacement in RLC-AA is expected to mimic the unphosphorylated RLC state, Glutamate replacement in RLC-EE the di-phosphorylated RLC state. RLC-AE is expected to mimic the mono-phosphorylated RLC state that is independent from upstream regulation, whereas RLC-AS and RLC-TA are phosphorylatable and coupled to upstream signaling in vitro and in vivo. Abbreviations used: Mm: *Mus musculus*, *Myl9* (NP_742116.1): Rn: *Rattus norvegicus*, *Myl9* (XP_006235463.1); Hs: *Homo sapiens*, *Myl9* (CAG33124.1); Xl: *Xenopus laevis*, *Myl9* (NP_001087016.1); Dr: *Danio rerio*, *Myl9b* (NP_998377.1); Dm: *Drosophila melanogaster*, *Sqh* (NP_511057.1). (**C**) Actin-activated ATP hydrolysis rate of RLC-TS and RLC mutants. Gray bars indicate the ATP hydrolysis rate at an actin concentration of 100 µM in the absence of RLC phosphorylation. Orange bars indicate the ATP hydrolysis rate at an actin concentration of 100 µM after RLC phosphorylation with MLCK, also indicated by a lowercase p. Note that the myosin activity in these assays are even lower than shown since direct actin-mediated hydrolysis of ATP likely accounts for a substantial portion of the ATPase of the unphosphorylated and mutant samples. (**D**) In vitro motility assay using RLC-TS and RLC mutants. No significant movement was observed for RLC-TS in the absence of MLCK phosphorylation and RLC-AA. n = 47--227 tracked filaments per RLC mutant. The data were corrected for the stage drift. (**E**) Actin cosedimentation assays of RLC-TS and RLC-AE, supernatants (S) and pellets (P) from mixtures of myosin, actin, and ATP as indicated. In the absence of actin, RLC-TS and RLC-AE remain in the supernatant. Binding of RLC-TS and RLC-AE to actin in the absence of ATP results in pelleting of the actomyosin complex. The presence of ATP disassembles the actomyosin complex and myosin mostly remains in the supernatant. The sedimentation of actin is independent of ATP. Soluble HMM fragments were used in this assay since myosin filaments sediment under the assay conditions. Red numbers indicate lanes.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.002](10.7554/eLife.20828.002)10.7554/eLife.20828.003Figure 1---figure supplement 1.Purification and characterization of wild-type and mutant *Drosophila* myosin (**A**) PageBlue-stained 4--12% Bis-Tris gel showing recombinant HMM (160 kDa) and full-length (228 kDa) RLC-TS or RLC mutants.RLC and mutant RLC (19 kDa) and the ELC (16 kDa) bind in a 1:1 stoichiometry to the myosin heavy chain, indicating that mutant RLCs bind with a similar affinity as RLC-TS. Data shown for RLC-AS HMM and full-length proteins are from different gels. (**B--F**) HPLC-mass spectrometry to detect phosphorylation events on the intact RLC. Each panel shows the deconvoluted mass spectrum of control RLC mutant (no MLCK, gray spectrum) at the top and RLC mutant after addition of MLCK (bottom, orange spectrum). A mass increase of 80 Da (HPO~3~ = 80 Da) corresponds to a single phosphorylation event. RLC-TS (**B**) can be phosphorylated by MLCK at two sites corresponding to Threonine-20 and Serine-21, RLC-AS (**C**) can be phosphorylated at one site corresponding to Serine-21, and RLC-TA (**D**) at one site corresponding to Threonine-20. No phosphorylation events are detectable for RLC-AA (**E**), RLC-AE (**F**), and RLC-EE (**G**) in agreement with the absence of phosphorylation sites.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.003](10.7554/eLife.20828.003)10.7554/eLife.20828.004Figure 1---figure supplement 2.Steady-state ATP-hydrolysis of RLC-TS (**A**) and RLC mutants (**B--F**).The dependence of steady-state ATP hydrolysis rate is plotted as a function of actin in the concentration range up to 100 µM. Data sets corresponding to the ATP hydrolysis rates in the absence of MLCK are shown in gray. Data sets corresponding to the ATP hydrolysis rates after RLC phosphorylation by MLCK are shown in orange.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.004](10.7554/eLife.20828.004)

Recent evidence has suggested that myosin motor activity is not essential for actin network contraction in some cases, but that myosin's main role is to function as an actin filament crosslinker ([@bib38]). Actin filament crosslinking could drive contraction in the absence of motor activity, if linked to actin network disassembly ([@bib54]). It was suggested that myosin motor activity is not required for apical constriction in epithelial cells of the neural tube, but that instead actin depolymerization was required for epithelial folding ([@bib12]). In addition, it was recently suggested that apical constriction during *Drosophila* dorsal closure results from cell volume reduction as opposed to myosin motor activity ([@bib49]). Thus, an important question is whether myosin motor activity has a role during apical constriction and tissue folding.

Common reagents used to test the necessity of myosin during cell and developmental processes are insufficient to determine the contribution of myosin motor activity. The ROCK inhibitor Y-27632 ([@bib59]) disrupts myosin filament assembly, motor activity, and prevents the motor domain from transitioning to the strong actin binding state by blocking RLC phosphorylation ([@bib51]). Furthermore, treatment with a ROCK inhibitor often disrupts myosin localization ([@bib24]; [@bib48]; [@bib58]). The myosin inhibitor blebbistatin locks the motor domain in a weak actin binding state, a state with similar affinity to actin as that of myosin bound to an unphosphorylated RLC ([@bib34]; [@bib46]). While RLC mutants thought to mimic the activated state of myosin have been observed to enable some *rock* mutant flies to survive to adulthood ([@bib63]), studies directly visualizing cell contractility determined that RLC mutants fail to suppress ROCK mutants ([@bib4]; [@bib30]; [@bib60]) or ROCK inhibition ([@bib43]), questioning whether these mutants truly mimic the phosphorylated state. Overexpression of a myosin heavy chain mutant that lacks the motor domain demonstrated the importance of myosin for force generation during morphogenesis; however, this approach would disrupt both motor and crosslinking functions ([@bib17]). Therefore, the relationship between myosin motor activity and cell and tissue shape change is unknown.

Defining the importance of myosin motor activity requires mutants with precisely characterized motor properties and quantitative analysis of cell and tissue shape changes. Previously, we made a series of *Drosophila* RLC mutants that substituted the phosphorylation sites with Alanine, as an unphosphorylatable residue or Glutamate, as a phosphomimetic ([@bib60]). Here we show for the first time that *Drosophila* myosin motor activity and myosin filament assembly are regulated by phosphorylation of the RLC. Additionally, we show that so-called phosphomimetic alleles of the RLC do not fully mimic the behavior of myosins associated with phosphorylated RLCs. Rather, they have graded and measurable motor activity defects compared to myosins with phosphorylated RLC, providing us with an allelic series of myosin motor mutants. We find that decreased motor activity is associated with slower cellular contractions and slower folding of epithelial tissue. Our results show that the reduction in the rate of apical constriction scales with the extent of the deficit in myosin motor activity.

Results {#s2}
=======

RLC mutants have reduced motor activity {#s2-1}
---------------------------------------

A prerequisite to systematically test the requirement of myosin motor activity during epithelial morphogenesis in *Drosophila* is to integrate in vitro and in vivo studies. Our approach included the preparation of wild-type myosin and RLC mutant myosins in sufficient amounts to biochemically characterize their kinetic, regulatory, and structural properties. This characterization of mutants with defined biochemical properties allows the precise interpretation of in vivo mutant phenotypes.

We first recombinantly overproduced and purified the heavy meromyosin (HMM) fragment and full-length *Drosophila* myosin in *Sf*9 insect cells ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Hereafter, the myosin holoenzyme with bound RLC is referred to as RLC-TS, where the phosphorylatable Threonine at position 20 and Serine at position 21 of the RLC are indicated ([Figure 1B](#fig1){ref-type="fig"}). Both sites are highly conserved between RLCs from higher eukaryotic myosins and their phosphorylation is expected to have an activating effect on the motor activity of *Drosophila* myosin ([Figure 1B](#fig1){ref-type="fig"}) ([@bib20], [@bib23]; [@bib28]).

To test whether phosphorylation of Threonine-20 and/or Serine-21 is a regulatory mechanism for *Drosophila* myosin, we examined the ability of MLCK to phosphorylate the RLC ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}) and used the actin-activated ATP hydrolysis rate under steady-state conditions as a readout for motor activity. The basal ATP hydrolysis rate (k~basal~) in the absence of actin was \~0.01 s^−1^ for RLC-TS, which is comparable to the rates of mammalian myosin isoforms ([Table 1](#tbl1){ref-type="table"}) ([@bib33]; [@bib35]). Actin marginally activated the ATP hydrolysis rate of RLC-TS in the absence of RLC phosphorylation. RLC phosphorylation potently activated myosin motor activity to a maximum ATP hydrolysis rate (k~cat~) of 1.23 ± 0.07 s^−1^ with an apparent actin affinity (K~app~) of 38.9 ± 7.32 µM ([Table 2](#tbl2){ref-type="table"} and [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). This result demonstrates that *Drosophila* myosin is regulated by RLC phosphorylation and that the effect of RLC phosphorylation in *Drosophila* is quantitatively similar to myosins from higher eukaryotes ([@bib20]).10.7554/eLife.20828.005Table 1.Comparison of the steady-state kinetic parameters between phosphorylated *Drosophila* and mammalian myosins.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.005](10.7554/eLife.20828.005)Parameter*Dm* myosin II\**Hs* myosin IIA^‡^*Hs* myosin IIB ^‡†^*Mm* myosin IIC ^‡†^*k~basal~* (s^−1^)0.01 ± 0.0010.021 ± 0.003\<0.004\<0.004*k~cat~* (s^−1^)1.23 ± 0.070.45 ± 0.030.17 ± 0.040.18 ± 0.04*K*~app~ (µM)38.9 ± 7.329 ± 23.4 ± 1.84.2 ± 1.1*k*~cat~/*K*~app~ (µM^−1^·s^−1^)\~0.03\~0.05\~0.05\~0.04[^3][^4][^5][^6]10.7554/eLife.20828.006Table 2.Steady-state ATP hydrolysis rates of RLC-TS and RLC mutants.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.006](10.7554/eLife.20828.006)**RLCk~basal~ (s^−1^)s.d.k~100~ (s^−1^)s.d.**RLC-TS0.0130.0070.120.03**RLC-TS0.0100.0010.820.01**RLC-AS0.0240.0050.150.02**RLC-AS0.0240.0080.810.04**RLC-TA0.0090.0020.120.01**RLC-TA0.0080.0020.370.01**RLC-AA0.0140.0060.160.03**RLC-AA0.0120.0020.230.02**RLC-AE0.0100.0020.210.03**RLC-AE0.0090.0020.230.01**RLC-EE0.0110.0070.190.01**RLC-EE0.0100.0020.220.01**[^7]

Next, we generated the RLC mutants RLC-AS, RLC-TA, RLC-AA, RLC-AE, and RLC-EE ([Figure 1B](#fig1){ref-type="fig"}). Rationale for the design of these mutants, which are routinely used in the *Drosophila* system, is that they have been assumed to represent the unphosphorylated, mono- or di-phosphorylated RLC states ([@bib28]; [@bib30]; [@bib43]; [@bib47]; [@bib48]; [@bib60]; [@bib63]). We tested the ability of MLCK to phosphorylate RLC mutants. We found that RLC-AS and RLC-TA can each be phosphorylated by MLCK at only one site, either Serine-21 or Threonine-20, respectively ([Figure 1---figure supplement 1C,D](#fig1s1){ref-type="fig"}). RLC-AA, RLC-AE, and RLC-EE were all unresponsive to MLCK treatment ([Figure 1---figure supplement 1E--G](#fig1s1){ref-type="fig"}). Thus, these mutants create a systematic series of myosins with motor activities that are either coupled (RLC-TA and RLC-AS) or uncoupled (RLC-AA, RLC-AE, and RLC-EE) from upstream signaling. This set of mutants also allowed us to individually determine the importance of phosphorylation of Threonine-20 and Serine-21 on myosin motor function.

Similar to RLC-TS, all RLC mutants have a low k~basal~ of \~0.01--0.02 s^−1^ ([Table 2](#tbl2){ref-type="table"}). Actin marginally activated the ATP hydrolysis rate of all RLC mutants to a similar extent ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). MLCK phosphorylation of RLC-AS increased its ATP hydrolysis rate to the same extent as that of the wild type RLC-TS ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). In contrast, phosphorylation of RLC-TA activated the ATP hydrolysis rate to a reduced extent ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}, and [Table 2](#tbl2){ref-type="table"}). The virtually identical steady-state ATP hydrolysis rates for RLC-TS and RLC-AS at 100 µM actin, but reduced activity of RLC-TA indicate that Serine-21 is the primary RLC phosphorylation site and that Threonine-20 is the secondary phosphorylation site. However, it is important to note that there is a slight reduction in the ATP hydrolysis rate of RLC-AS at lower actin concentrations ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}).

The almost linear dependence of the ATP hydrolysis rates of all RLC mutants on actin in the concentration range up to 100 µM ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) shows that both, the k~cat~ and the K~app~ are not experimentally accessible. The direct comparison of the ATP hydrolysis rates of RLC-TS and RLC mutants at 100 µM actin (k~100~), the highest actin concentration used in the assay, shows that phosphorylation results in a \~6--7 fold activation for RLC-TS and RLC-AS versus a \~3 fold activation for RLC-TA, respectively ([Figure 1C](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Surprisingly, RLC-AE and RLC-EE display a k~100~ that was similar to that of RLC-AA and only 27--28% of the motor activity of phosphorylated RLC-TS ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2D--F](#fig1s2){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}). This result demonstrates that neither RLC-AE nor RLC-EE successfully mimic RLC phosphorylation at Serine-21.

To test the functional activity of purified RLC-TS and RLC mutants, we performed an in vitro motility assay to measure the speed at which the motors translocate actin filaments across the surface of a coverslip. No significant movement was detected for RLC-TS in the absence of phosphorylation, consistent with myosin being in an inactive, weak actin-binding state. Phosphorylation of RLC-TS by MLCK resulted in movement of actin filaments at \~250 nm s^−1^, which is slightly higher than that of human myosin IIA ([Figure 1D](#fig1){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}) ([@bib10]). No obvious directed actin filament movement was observed for RLC-AA, consistent with this mutant mimicking the unphosphorylated RLC state. Phosphorylated RLC-AS moved actin filaments at 50% of the rate of phosphorylated RLC-TS and phosphorylated RLC-TA moved actin filaments at only 10% of the rate of phosphorylated RLC-TS. These results are consistent with Serine-21 being the primary phosphorylation site ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Both, RLC-AE and RLC-EE translocated actin filaments, demonstrating that these mutants exhibit some level of constitutive functional activity; however, translocation speeds of actin filaments by RLC-AE and RLC-EE were only about 30% of that of phosphorylated RLC-TS, indicating a functional deficit for these mutants ([Figure 1D](#fig1){ref-type="fig"}). Though neither unphosphorylated RLC-TS nor RLC-AA translocated actin filaments in the in vitro motility assay, both motors tethered actin filaments to the surface indicating that unphosphorylated *Drosophila* myosin still binds actin weakly as occurs with mammalian unphosphorylated myosins, suggesting that bipolar filaments containing these myosins could cross-link or tether actin filaments ([@bib10]).10.7554/eLife.20828.007Table 3.Comparison of *Drosophila* and mammalian myosin filament dimensions.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.007](10.7554/eLife.20828.007)Parameter*Dm* myosin-II\*,^†^*Hs* myosin IIA^‡^*Hs* myosin IIB^‡^*Hs* myosin IIC^‡^Mean number of myosins per filament12.8 ± 4.5\* 14.9 ± 3^†^293014Mean bare zone length (nm)194 ± 21\* 204 ± 19^†^167 ± 19166 ± 16219 ± 13Filament length (nm)312 ± 25\*301 ± 24323 ± 24293 ± 33Sliding velocity (nm·s^−1^)247 ± 3782^§^n.d.n.d.[^8][^9][^10][^11]

To determine if the RLC-AE mutant drastically changes the myosin kinetic pathway, we performed an actin co-sedimentation assay to determine whether the mutant myosin binds to actin in a nucleotide-dependent manner. Actin is sedimented by high centrifugal forces regardless of the ATP concentration (lanes 13--16). Neither RLC-TS nor RLC-AE alone sediment without actin (lanes 1,2 and 7,8). When mixed with actin both RLC-TS and RLC-AE bind and sediment in the absence, but not the presence of ATP (lanes 3--6, 9--12). This suggests that RLC-TS and RLC-AE still cycle through strongly- and weakly-actin bound states during the kinetic cycle. Together, these results indicate that RLC-TS and RLC mutants likely use the same kinetic pathway, but that RLC-AE and RLC-EE do not fully recapitulate the behavior of myosin bearing wild type RLC. The RLC-AA mutant mimics the known functions of unphosphorylated RLC-TS in that it does not move actin in the in vitro motility assay, but does tether actin to the surface.

RLC mutants can form bipolar filaments {#s2-2}
--------------------------------------

Because myosin assembly into bipolar filaments is critical for both motor-dependent and motor-independent functions, such as translocation and crosslinking of actin filaments, we examined the ability of recombinant RLC-TS and RLC mutants to assemble into filaments. Electron micrographs show that RLC-TS and RLC mutants form small bipolar filaments, with a length of 312 ± 25 nm and a width of 7.4 ± 1.3 nm that consist of 12.8 ± 4.5 myosin molecules ([Figure 2](#fig2){ref-type="fig"}). The appearance of the filaments is similar to the rotary shadowed images of myosin purified from *Drosophila* cells and those formed by mammalian myosin IIC ([Table 3](#tbl3){ref-type="table"}) ([@bib6]; [@bib32]).10.7554/eLife.20828.008Figure 2.Appearance and assembly of RLC-TS and RLC mutants into filaments.RLC-TS and RLC mutants form predominantly filaments in the absence of ATP (−ATP) and disassemble into the 10S conformation in the presence of ATP (+ATP). Phosphorylation of Threonine-20 or Serine-21, indicated +ATP/MLCK, stabilize the filaments in the presence of ATP. Scale bar = 100 nm.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.008](10.7554/eLife.20828.008)

We also revealed that full-length RLC-TS is in a two-state equilibrium, which involves a compact folded (10S) conformation and assembled filaments. The equilibrium is shifted from the filamentous form to the 10S conformation in the presence of ATP when the RLC is not phosphorylated ([Figure 2](#fig2){ref-type="fig"}). Similar to RLC-TS, all RLC mutants form filaments in the absence of ATP and disassemble into the 10S conformation in the presence of ATP ([Figure 2](#fig2){ref-type="fig"}). As occurs with mammalian myosin II paralogs, phosphorylated RLC-TS remains predominantly filamentous in the presence of ATP demonstrating a dual effect of phosphorylation; activation of the ATPase activity and stabilization of the filament structure (28). Phosphorylation also stabilizes filaments of RLC-AS and RLC-TA in the presence of ATP. If RLC-AE and RLC-EE were faithfully mimicking the phosphorylated RLC state, they should also remain predominantly filamentous in ATP in vitro at these protein concentrations; instead, addition of ATP to RLC-AA, RLC-AE and RLC-EE results in depolymerization of the myosin filaments. These results demonstrate that the RLC-AS and the RLC-TA mutants exhibit phosphoregulation by upstream kinases similar to RLC-TS ([Figure 2](#fig2){ref-type="fig"}). The concentration of myosin in *Drosophila* cells is on the order of 0.5 µM, which favors the filamentous form and thus making it likely that all RLC mutants form filaments in vivo ([@bib32]; [@bib60]). However, the assembly of RLC-AE and RLC-EE mutants in cells would not be governed by kinases. Thus, these RLC phosphomutants are not only uncoupled from the control of signal transduction pathways that regulate myosin phosphorylation, but also display motor defects. These properties together prohibit RLC-AE and RLC-EE from being good models for phosphorylated myosin.

*RLC-TA* and *RLC-AE* exhibit reduced tissue tension in vivo {#s2-3}
------------------------------------------------------------

We and others have constructed RLC mutants in *Drosophila* that affect the Threonine-20 and Serine-21 phosphorylation sites ([@bib28]; [@bib30]; [@bib60]). Our mutant light chains are fused to GFP and expressed from the endogenous RLC promoter in a mutant background that reduces the expression of endogenous *RLC-TS*. We have quantified that there is 90% RLC mutant transgene expression and 10% endogenous *RLC-TS* in our experimental setup ([@bib60]). To determine whether tissues expressing RLC mutants exhibit normal levels of apical myosin, we imaged pairs of embryos side-by-side, one *RLC-TS* and one RLC mutant, to compare apical myosin levels under identical imaging conditions ([Figure 3A](#fig3){ref-type="fig"}). Using this method, we demonstrated that the final apical myosin intensity in folding tissues was similar between *RLC-TS* and RLC mutant embryos ([Figure 3A,B](#fig3){ref-type="fig"}). These side-by-side comparisons of apical myosin levels, and our previous results where we showed that the *RLC-AA* mutant localized apically (23), demonstrate that neither full myosin motor activity nor targeted phosphorylation is required for apical myosin localization.10.7554/eLife.20828.009Figure 3.Myosin mutants with reduced motor activity exhibit reduced tissue recoil following laser ablation.(**A--B**) Myosin intensity in pair of embryos expressing *RLC-TS* and *RLC-TA* (**A**) or *RLC-TS* and *RLC-AE* (**B**) are comparable. The images represent embryos mounted side-by-side and imaged at the same time to compare myosin intensity under identical imaging conditions. Plots (right) show the peak mean intensity profile of myosin signal along a horizontal line spanning each embryo. Scale bars = 10 µm. (**C**) Initial wound recoil is less pronounced in tissues expressing RLC mutants than in *RLC-TS* tissue. Time-lapse images of embryos expressing indicated RLC mutant. Between time 0 s and 1.3 s an 8.5 μm incision in the tissue was made, indicated by the vertical yellow line. Scale bars = 5 µm. (**D**) Mean displacement of wound edge following tissue ablation (n = 15 *RLC-TS* embryos, n = 11 *RLC-TA* embryos, n = 10 *RLC-AE* embryos). Shaded area is +/− one standard deviation. (**E**) Initial recoil velocity is higher in *RLC-TS* tissue. The initial recoil velocity was calculated by fitting the displacement to a Kelvin-Voigt model and taking the derivative of the fit at time zero. Central line in box plot is the median, the box edges are the 25th and 75th percentiles, and the whiskers represent the distribution minima and maxima (n = 14 *RLC-TS* embryos, n = 10 *RLC-TA* embryos, n = 9 *RLC-AE* embryos).**DOI:** [http://dx.doi.org/10.7554/eLife.20828.009](10.7554/eLife.20828.009)10.7554/eLife.20828.010Figure 3---figure supplement 1.*RLC-TS* and RLC mutant do not exhibit clear differences in viscoelastic properties.Exponents (α) of power laws fit (**A**) and time decay constants (τ) of Kelvin-Voigt fits (**B**) to displacements of wound edges after tissue ablation are not significantly different between *RLC-TS*, *RLC-TA* and *RLC-AE* tissues. Box-and-whisker plots display the median (central line), 25th and 75th percentiles (box edges), and the most extreme data points not considered outliers (whiskers) (n = 14 *RLC-TS* embryos, n = 10 *RLC-TA* embryos, n = 9 *RLC-AE* embryos).**DOI:** [http://dx.doi.org/10.7554/eLife.20828.010](10.7554/eLife.20828.010)

If the *RLC-AE* and *RLC-EE* mutants faithfully mimicked the phosphorylated RLC state in vivo, these so-called phosphomimetic mutants might be expected to result in increased tension relative to *RLC-TS* embryos. In our in vivo studies, we focused our analysis on the *RLC-AE* mutant, because the *RLC-EE* mutant often results in altered embryo shape, likely due to defects in oogenesis ([@bib60]). Laser-cutting techniques have been used to infer the levels of tension in epithelial tissues ([@bib15]; [@bib16]; [@bib25]; [@bib37]; [@bib40]). In response to a laser cut, the tissue adjacent to the incision will exhibit quick recoil away from the cut, followed by slower movement away from the cut site before the wound begins to heal and close. The initial rapid displacement of surrounding tissue, the initial recoil velocity, is proportional to the tension in the tissue just prior to the cut, assuming constant tissue viscosity ([@bib37]) (see Materials and methods). Therefore, we compared the initial recoil velocity after tissue cutting in wild-type (*RLC-TS*) and RLC mutant embryos.

During ventral furrow formation in the developing *Drosophila* embryo, tension is highest along the anterior-posterior axis of the furrow ([@bib39]). To infer tension in various RLC mutants, we made 8.5 μm long cuts across the width of the furrow at equivalently staged embryos and tracked the displacement of the wound edge along the anterior-posterior axis ([Figure 3C,D](#fig3){ref-type="fig"}). We calculated the initial recoil velocity (see Materials and methods) and found that tissues expressing either *RLC-TA* or *RLC-AE* display lower initial recoil velocities than *RLC-TS* tissues, suggesting that RLC mutant tissues generate less tension than *RLC-TS* tissues ([Figure 3D,E](#fig3){ref-type="fig"}). Note that this interpretation assumes that viscous drag is not different between tissues of mutant and *RLC-TS* embryos. Previously, altering the level of myosin phosphorylation was proposed to alter the viscoelastic properties of a tissue, as measured by a change in the exponent used when fitting the data to a power law ([@bib16]). We found that the mean power law exponent values for *RLC-TS, RLC-TA* and *RLC-AE* were 0.3, 0.3 and 0.4, respectively ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Differences between the power law exponents of *RLC-TS*, *RLC-TA*, and *RLC-AE* embryos were not significant ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Furthermore, we determined the time decay constants calculated from fitting recoil distance to a Kelvin-Voigt model, which are proportional to the ratio of the viscosity coefficient of the tissue to its stiffness. In agreement with power law exponents, differences between time decay constants of RLC-TS, RLC-TA, and RLC-AE embryos were not significant ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). We suggest that the 3-fold decrease in initial recoil velocity in the *RLC-AE* mutant reflects decreased tension for the following reasons: (I) The power law exponent and time decay constant are similar between *RLC-TS* and *RLC-AE*, suggesting similar viscoelastic properties; (II) Myosin levels are similar between *RLC-TS* and *RLC-AE*; (III) The *RLC-AE* mutant can still interact with actin, suggesting that there is not necessarily a difference in the amount of actomyosin present in the tissue; and (IV) *RLC-AE* exhibited a reduced maximal recoil distance ([Figure 3D](#fig3){ref-type="fig"}), which is also consistent with decreased tissue tension. We conclude that myosin motor activity is important to generate epithelial tension during ventral furrow formation.

Apical constriction rate scales with the measured in vitro myosin motor activity {#s2-4}
--------------------------------------------------------------------------------

Understanding the contribution of the myosin motor to in vivo tissue folding requires having biochemically defined mutants or inhibitors that affect myosin motor activity. *Drosophila* myosin is insensitive to blebbistatin, a widely-used myosin inhibitor ([@bib22]; [@bib53]), which has limited tests of in vivo myosin function to genetic disruptions or dominant negative approaches that do not specifically disrupt motor activity ([@bib17]). Furthermore, inhibition of ROCK, a kinase that phosphorylates the RLC, completely disrupts myosin localization and does not distinguish between myosin motor and crosslinking functions ([@bib48]). Although RLC-EE enables some *rock* mutant flies to survive to adulthood ([@bib63]), apical constriction, tissue extension, and collective cell migration defects of *rock* mutants or ROCK inhibition are not suppressed by expressing the *RLC-EE* allele, suggesting that ROCK could have other important functional targets besides myosin or that RLC-EE does not mimic the phosphorylated state ([@bib4]; [@bib30]; [@bib43]; [@bib60]). The in vivo effects of *RLC-AA* have already been reported ([@bib60]). These mutants have defects in cellularization, which precedes tissue folding ([@bib60]; [@bib65]). It is likely that the RLC-AA mutant is not able to oligomerize at all, in contrast to RLC-AE and RLC-EE, which form aggregates with heavy chain in vivo ([@bib60]). In addition, because we demonstrated that RLC-AS, RLC-TA, and RLC-AE have variable deficits in motor activity that define an allelic series in vitro, these mutants were ideal to assess the in vivo roles of myosin motor activity during apical constriction.

To test the functional consequence of reducing myosin motor activity, we examined whether the *RLC-AE*, *RLC-TA*, and *RLC-AS* mutants constrict cells as well as *RLC-TS*. Because (I) there is great heterogeneity in the timing and rate of myosin accumulation between different cells and (II) the rate of myosin accumulation, as measured with apical RLC::GFP intensity, is correlated with the degree of constriction ([@bib64]), the direct comparison of different RLC alleles required normalization for differences in myosin accumulation rates. To identify instances of rapid cellular constriction, we first smoothed signals for apical area and mean myosin intensity and calculated instantaneous rates for each time point. To normalize for differences in myosin accumulation rates, we identified times of rapid myosin intensity increase and selected time periods where myosin accumulated at a given rate (i.e. one to two standard deviations above the mean rate for *RLC-TS* cells). We calculated and compared constriction rates at these instances. Thus, we determined whether the same rate of apical myosin accumulation results in equivalent constriction rates in embryos expressing RLC mutants when compared to *RLC-TS*. We found that the mean constriction rate for cells in *RLC-AS* was 74% of that of *RLC-TS* cells ([Figure 4A](#fig4){ref-type="fig"}). This defect was consistent with the lower RLC-AS ATPase activity at intermediate actin concentrations and the lower actin gliding velocity of the RLC-AS mutant ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). We found that cells expressing *RLC-TA* or *RLC-AE* constricted with mean rates that were 60% and 47% of RLC-TS cells, respectively ([Figure 4A](#fig4){ref-type="fig"}). The greater defect of the *RLC-TA* mutant, compared to *RLC-AS* was consistent with the Serine-21 site being the primary site responsible for myosin motor activation in *Drosophila* myosin, similar to mammalian myosins ([@bib7]; [@bib20]; [@bib26]). Furthermore, on average, cells expressing *RLC-AE* constricted slower than those expressing *RLC-TA* ([Figure 4C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Taking our in vivo and in vitro measurements of myosin activity, there is a relationship between myosin motor activity and constriction rate ([Figure 4B](#fig4){ref-type="fig"}). On the tissue-scale, the slower constriction is associated with a delay in tissue folding and sealing. The *RLC-AE* mutant, which had the greatest defect in motor activity, exhibited the slowest tissue folding behavior, with minimal folding occurring even 9 min after myosin first appeared ([Figure 4C](#fig4){ref-type="fig"}). The *RLC-AS* and *RLC-TA* mutants exhibited tissue folding at intermediate rates, folding over, but failing to seal after 9 min, a time in which *RLC-TS* is fully sealed ([Figure 4C](#fig4){ref-type="fig"}). Furthermore, the amount of time it takes the mean apical area to decrease to 50% of the starting apical area recapitulates the previously observed pattern: the *RLC-AE* mutant takes longest time (10.4 min) to reach 50% of the initial mean apical area, while the *RLC-AS* and *RLC-TA* mutants take an intermediate amounts of time (7.0 min and 7.4 min, respectively) relative to the wild-type *RLC-TS* (6.8 min) ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Overall, our results show that the apical constriction rate and tissue folding rate scales with the myosin motor activity.10.7554/eLife.20828.011Figure 4.Apical constriction rate scales with measured in vitro myosin motor activity.(**A**) *RLC-AS*, *RLC-TA*, and *RLC-AE* cells generate weaker constrictions than *RLC-TS* cells. Central line in box plot is the median, the box edges are the 25th and 75th percentiles, and the whiskers represent the distribution minima and maxima, not considered outliers; outliers are plotted individually (n = 338 constriction instances identified from 138 cells from two embryos for *RLC-TS*; n = 311 constriction instances identified 152 cells from three embryos for *RLC-AS*; n = 630 constriction instances identified from 268 cells from three embryos for *RLC-TA*; n = 265 constriction instances identified from 187 cells from three embryos for *RLC-AE*). (**B**) Constriction rate corresponds with actin-activated ATPase activity. Bars represent the standard deviation of the measurements. (**C**) Tissue invagination and apical constriction is slower in the *RLC-TA* mutant and slowest in the *RLC-AE* mutant. Time-lapse images are representative tissues from embryos expressing the indicated RLC mutant and Membrane::Cherry (membrane). Schematics illustrate plane images were acquired in. Scale bars = 10 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.011](10.7554/eLife.20828.011)10.7554/eLife.20828.012Figure 4---figure supplement 1.Timing of tissue contraction scales with in vitro myosin motor activity.(**A**) Aligned mean apical area over time for representative embryos. (**B**) Time it takes for tissue contraction to 50% the starting mean apical area (A~0~). *RLC-AE* tissue constricts slowest compared to wild-type *RLC-TS*. Additionally, on average, *RLC-TA* constricts slower than *RLC-AS*.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.012](10.7554/eLife.20828.012)

Discussion {#s3}
==========

Whether myosin motor activity is required during tissue morphogenesis has not been clearly determined. Here, we combine in vitro analysis of the motor activity of RLC-TS and RLC mutants with in vivo characterization of force-generation by these motors at the cellular- and tissue-scales. A major advantage of our approach is that we have characterized the enzymatic properties of wild-type and mutant motors and quantified the in vivo effects of these motors within a single species, *Drosophila*. Such a systematic approach was essential to show that myosin motor activity is required for cellular contraction and to generate tension to fold epithelial tissues during *Drosophila* morphogenesis.

*Drosophila* has increasingly been used as a model system to understand the role of myosin in tissue morphogenesis. One significant advantage of *Drosophila* over mammalian systems is that *Drosophila* only has one gene encoding the myosin heavy chain, unlike the case with mammals where multiple myosin paralogs are expressed from three genes ([@bib19]; [@bib31]; [@bib52]). So far, it was assumed that *Drosophila* myosin is regulated identically to mammalian myosins by RLC phosphorylation although this cannot necessarily be assumed because striated muscle myosins from different species respond differently to RLC phosphorylation. For example, phosphorylation of the equivalent Serine residue in mammalian striated muscle myosin only slightly modulates the enzymatic and mechanical properties of the motor whereas in some invertebrates muscles, such as *Limulus* and *Tarantula*, phosphorylation of this site is an on/off switch as is found in mammalian non-muscle myosins ([@bib9]; [@bib42]; [@bib50]). Here, we show for the first time that recombinant *Drosophila* myosin is regulated in an on/off manner by RLC phosphorylation. Phosphorylation of the RLC at Threonine-20 or Serine-21 activates myosin motor activity in addition to promoting the formation of bipolar filaments composed of 12.8 myosins under physiological conditions in vitro. Our study also shows that RLC phosphorylation at Threonine-20 results in different mechanoenzymatic properties than phosphorylation at Serine-21, in agreement with Serine-21 being the primary phosphorylation site ([@bib7]). The similarity in regulatory properties between *Drosophila* myosin and vertebrate myosins qualifies *Drosophila* as an excellent model organism to study the underlying principles of myosin function and regulation in complex processes such as cell contraction and tissue folding.

RLC phosphorylation provides a means for spatial or temporal control of actomyosin contractility in cells. Mutants of the RLC phosphorylation sites in both *Drosophila* and mammalian cells have been used to test the role of RLC phosphorylation and its upstream regulation by signal transduction pathways in controlling myosin's activity and spatial distribution. Mutation of both Threonine-20 and Serine-21 to Alanines results in a myosin with properties similar to that of unphosphorylated mammalian myosin; the ATPase activity is low, there is no detectable movement of actin filaments in the in vitro motility assay and the myosin does not form filaments in the presence of ATP. In contrast and consistent with interpretations of past in vitro studies of smooth muscle myosin, we systematically show that substitution of phosphorylation sites of *Drosophila* RLC with negatively charged residues (RLC-AE and RLC-EE) does not fully mimic the effects of phosphorylation of Serine-21 and Threonine-20 with respect to both the enzymatic and motile properties of the myosin ([@bib7]; [@bib13]; [@bib29]; [@bib55]). In addition, these mutants do not exhibit stable filament formation in vitro in the presence of ATP as occurs with phosphorylated wild type myosin. Furthermore these mutations would uncouple myosin activity from regulation by upstream kinases in vivo and in vitro ([Table 2](#tbl2){ref-type="table"}) ([@bib61]). The constitutive activity of these so-called phosphomimetic mutants was significantly lower than that of phosphorylated RLC-TS ([Figure 1C](#fig1){ref-type="fig"}), demonstrating that acidic residues are not sufficient to mimic the effect of phosphate moieties on Threonine-20 or Serine-21 of the RLC. This inadequacy is most likely due to substantial chemical differences between the phosphorylated amino acid side chain and the surrogate side chain, including size and formal charge at physiological pH. Reasons for the inability of negatively charged amino acids to recapitulate the phosphorylated RLC state include an allosteric communication pathway that involves the RLC, the ELC and the myosin motor domain and structurally requires the presence of a phosphate moiety ([@bib13]). The results from the Glutamate replacements (RLC-AE and RLC-EE) in the current study together with results from recent molecular dynamic simulation study ([@bib13]) lead us to hypothesize that mutant RLCs in which Aspartate is used as a replacement to mimic phosphorylation would also fail to faithfully mimic the phosphorylated RLC state ([@bib13]; [@bib29]; [@bib57]). Taken together, our in vitro and in vivo data strongly suggests that caution should be used when interpreting the phenotype of so-called phosphomimetic RLC mutants in *Drosophila* and mammalian systems.

This study demonstrates that these RLC phosphomutants define an allelic series that can be used to test the function of myosin motor activity in morphogenetic processes in *Drosophila. Drosophila* myosin is insensitive to the pharmacological inhibitor blebbistatin ([@bib22]; [@bib53]) and, until now, biochemically defined myosin mutants were unavailable. The *RLC-AS* mutant exhibited the smallest decrease in ATP hydrolysis rate at intermediate actin concentrations and also exhibited a marginal decrease in the in vivo constriction rate. The phosphorylation conditions of our in vitro biochemical experiments should result in phosphorylation primarily or exclusively at Serine-21. The results of our paper show that although Serine-21 is clearly the primary phosphorylation site, phosphorylation at Threonine-20 alone results in reduced actin-activated ATPase activity and a slower rate of actin filament sliding. Substituting an Alanine for Threonine-20 lowered the rate of actin filament sliding and had lower ATPase activity if assayed at low actin concentrations since the K~app~ for this mutant was higher than for RLC-TS. This mutation (*RLC-AS*), when made in vivo also resulted in a reduced apical constriction rate, consistent with motor activity driving constriction. The *RLC-TA* mutant exhibited an intermediate defect in both in vitro and measured in vivo activities. Finally, the *RLC-AE* mutant had the most severe defect in the ATP hydrolysis rate and correspondingly had the most significant defect in constriction rate and tissue folding. Past work has suggested that *RLC-EE* can promote contraction ([@bib1]; [@bib11]; [@bib30]). However, this result is only obtained when the *RLC-EE* is expressed in a background where wild-type *RLC-TS* is also present. Myosin molecules can form mixed filaments (i.e. hetero-oligomers) with other myosins ([@bib5]). Thus, *RLC-EE* is likely forming mixed filaments with phosphorylated wild-type *RLC-TS* and recruiting the entire complex to an abnormal location to result in the excessive constriction. Importantly, *RLC-EE* is incapable of contraction without ROCK ([@bib30]; [@bib43]; [@bib60]), suggesting that the wild-type phosphorylatable *RLC* is responsible for excessive cellular contraction in these experiments. Importantly, our in vitro motility assay results demonstrate that the phosphomutants RLC-AA, RLC-AE, and RLC-EE are clearly not mimicking phosphorylation, but can still bind F-actin. This is important because it suggests that these mutants can function as cross-linkers, if they oligomerize, but translocate actin more slowly when compared with the phosphorylated and unphosphorylated RLC-TS. In summary, motor activity scaled with in vivo contractile activity. Given this relationship, we propose that myosin motor activity determines the contraction rate during apical constriction and tissue folding. In the future, it will be important to determine whether other properties of myosin, like actin crosslinking, serve other roles during tissue morphogenesis.

Materials and methods {#s4}
=====================

Recombinant overproduction and purification of *Drosophila* myosin and other proteins {#s4-1}
-------------------------------------------------------------------------------------

cDNA constructs encoding N-terminally Halo-tagged full-length *Drosophila* myosin (amino acids 1--1971, accession number NP_001014553.1) and the HMM construct comprising amino acids 1--1363 were generated with standard cloning techniques. A polycistronic vector comprising the genes for *Sqh* (accession number NP_001284930.1) and *Mlc-c* (accession number NP_511049.1) was used for the expression of both light chain genes. Mutations of the cDNA at sites corresponding to amino acids Threonine-20 and Serine-21 of the RLC were made using the Quickchange XL kit (Agilent Technologies) to create the RLC mutants RLC-AA, RLC-AE, RLC-AS, RLC-EE, RLC-TA, and RLC-AS according to [Figure 1B](#fig1){ref-type="fig"}. Transposition, the generation of recombinant baculoviruses, protein production and purification were performed as described previously via Flag affinity chromatography ([@bib22]) with minor modifications. HMM was further purified to electrophoretic homogeneity with size exclusion chromatography on a HiLoad 16/600 Superdex 200 pg column (GE Healthcare). Full-length myosin was dialyzed in low salt buffer containing 10 mM MOPS pH 7.2, 25 mM NaCl, 0.1 mM EGTA, 3 mM NaN~3~, 5 mM MgCl~2~, and 2 mM DTT, concentrated by low speed centrifugation (4000xg, 15 min) and dissolved in 10 mM MOPS pH 7.2, 0.1 mM EGTA, 3 mM NaN~3~, 500 mM NaCl, and 1 mM DTT. Actin was prepared from rabbit skeletal muscle acetone powder (Pel-Freez Biologicals) as described previously ([@bib22]). Rabbit smooth muscle MLCK and rat calmodulin were recombinantly overproduced in *Sf*9 insect cells and *E.coli* and purified as described ([@bib62]).

HPLC-mass spectrometry {#s4-2}
----------------------

RLC-TS and RLC mutant HMMs (1--2.5 µM) were phosphorylated overnight in buffer containing 10 mM MOPS pH 7.3, 150 mM KCl, 5 mM MgCl~2~, 0.2 mM CaCl~2~, 0.1 mM EGTA, 1 mM DTT, 0.1 µM CaM, 0.2 mM ATP, 10 µg/mL MLCK, and 1x phosphatase inhibitor cocktail PhosSTOP (Roche, Indianapolis, IN) at 4°C. The conditions favor phosphorylation of both Threonine-20 and Serine-21 on RLC-TS whereas shorter incubation times favor phosphorylation of only Serine-21. MLCK was omitted for the unphosphorylated controls. A volume of 5--8 µl of the proteins was injected into a reverse phase HPLC (Agilent 1100 series HPLC, Agilent Technologies) with a Zorbax 300 SB-C18 (2.1×50 mm, 3.5 M, Agilent Technologies) and introduced into the mass spectrometer as described ([@bib3]; [@bib56]). Positive ion Electrospray Ionization (ESI) mass spectra for intact protein were obtained with an Agilent 6224 mass spectrometer equipped with an ESI interface and a time-of-flight (TOF) mass detector (Agilent Technologies). Mass spectra were analyzed and deconvoluted using MassHunter version B.06.00 (Agilent Technologies) software.

ATPase activity and in vitro motility assay {#s4-3}
-------------------------------------------

Basal and actin-activated ATPase activities of HMM were determined using an NADH-linked assay as described previously ([@bib22]) at 25°C in buffer containing 10 mM MOPS (pH 7.0), 50 mM NaCl, 2 mM MgCl~2~, 2 mM ATP, 0.15 mM EGTA, 40 units/mL lactate dehydrogenase, 200 units/mL pyruvate kinase, 1 mM phosphoenolpyruvate, 0.2 mM NADH and varying concentrations of filamentous actin (0--100 µM). Myosin HMM was phosphorylated at room temperature for a minimum of 30 min prior to the assay by the addition of 0.2 mM ATP, 0.2 mM CaCl~2~, 0.1 µM CaM, and 10 µg/mL MLCK. To determine the kinetic constant k~cat~ and K~app~ experimental data sets were fit to the Michaelis-Menten equation using Origin 8.5 (OriginLab). The reported data represent the means and s.e. from at least four separate experiments. The in vitro motility assay was performed as described previously with full-length myosin in the presence or absence of MLCK phosphorylation ([@bib27]).

Actin-sedimentation assay {#s4-4}
-------------------------

0.7 µM RLC-TS and RLC-AE HMM were incubated with 10 µM filamentous actin under nucleotide-free conditions or in the presence of 1 mM ATP in buffer containing 10 mM MOPS pH 7.3, 100 mM NaCl, 2 mM MgCl~2~, 0.1 mM EGTA, 3 mM NaN~3~ and 1 mM DTT for 30 min at room temperature. Samples only containing RLC-TS, RLC-AE or filamentous actin were used as a control to access the sedimentation behavior. The samples were centrifuged (100,000xg, 30 min, 4°C) in a Beckman Optima MAX-XP. Supernatant and pellet fractions were separated and supplemented to an equivalent volume with loading buffer and 15 µl analyzed on a 4--12% Bis-Tris gel (Life Technologies). The gel was stained with PageBlue (Fermentas) and scanned on an Odyssey system (LiCor).

Electron microscopy {#s4-5}
-------------------

Myosin was diluted to 100 nM in buffer containing 150 mM NaCl, 10 mM MOPS, 0.1 mM EGTA, 2 mM MgCl~2~ (pH 7.0), (supplemented with 100 μM ATP where required). Samples were applied to the grid immediately after dilution. 3 μl of sample was applied to UV treated, carbon-coated copper grid and stained with 1% uranyl acetate. Micrographs were recorded on a JEOL 1200EX II microscope using an AMT XR-60 CCD camera, operating at 80.0 kV room temperature. Catalase crystals were used as a size calibration standard.

Fly stocks and genetics {#s4-6}
-----------------------

Fly stocks used in this study are listed in [Table 4](#tbl4){ref-type="table"}. *sqh* is the *Drosophila* gene for the myosin RLC. Briefly, we used *sqh-XX::GFP* alone and *sqh-XX::GFP* recombined with *Gap43::mCherry* (a plasma membrane) mutant stocks crossed into the *sqh^1^* hypomorph background, generated in [@bib60]. Germline clones were generated using the FLP-DFS technique by heat shocking mutant/*ovo^D^ *larvae for 2 hr at 37°C for 3--4 d ([@bib8]). Briefly, *sqh^1^* FRT/FM7; *sqh-XX::GFP*/CyO females were crossed to *ovo^D^ *FRT/Y; *hsFlp* males, the resulting larvae were heat shocked, and *sqh^1^* FRT/*ovo^D^ *FRT; *sqh-XX::GFP/hsFlp* females were crossed to OreR to collect embryos that resulted from *sqh^1^* mutant germline clones and also express *sqh-XX::GFP*. Throughout the manuscript, the notation distinguishes between recombinant RLC mutant protein and embryos expressing the RLC mutants by using normal (RLC-TS) versus italic (*RLC-TS*) type, respectively.10.7554/eLife.20828.013Table 4.Fly stocks.**DOI:** [http://dx.doi.org/10.7554/eLife.20828.013](10.7554/eLife.20828.013)**GenotypeSourceRRID for associated stocks or alleles\***Oregon-R-C (wild type)2RRID: FBst0000005ovo^D1^FRT^101^/Y; hsFLP-38/hsFLP-382ovoD1RRID: FBst0001813sqh^1^FRT^101^/FM7; P{w^+^sqh-TS::GFP}attP1/CyO1sqh^1^ sqh-TSRRID: FBal0016066RRID: FBal0298052sqh^1^FRT^101^/FM7; P{w^+^sqh-AS::GFP}attP1/CyO1sqh^1^ sqh-ASRRID: FBal0016066RRID: FBal0298055sqh^1^FRT^101^/FM7; P{w^+^sqh-TA::GFP}attP1/CyO1sqh^1^ sqh-TARRID: FBal0016066RRID: FBal0298054sqh^1^FRT^101^/FM7; P{w^+^sqh-AE::GFP}attP1/CyO1sqh^1^ sqh-AERRID: FBal0016066RRID: FBal0298057sqh^1^FRT^101^/FM7; P{w^+^sqh-TS::GFP}attP1 P{w^+^Gap43::mCherry}attP40/CyO1sqh^1^ sqh-TS Gap43RRID: FBal0016066RRID: FBal0298052RRID: FBtp0087760sqh^1^FRT^101^/FM7; P{w^+^sqh-AS::GFP}attP1 P{w^+^Gap43::mCherry}attP40/CyO3sqh^1^ sqh-AS Gap43RRID: FBal0016066RRID: FBal0298055RRID: FBtp0087760sqh^1^FRT^101^/FM7; P{w^+^sqh-TA::GFP}attP1 P{w^+^Gap43::mCherry}attP40/CyO1sqh^1^ sqh-TA Gap43RRID: FBal0016066RRID: FBal0298054RRID: FBtp0087760sqh^1^FRT^101^/FM7; P{w^+^sqh-AE::GFP}attP1 P{w^+^Gap43::mCherry}attP40/CyO1sqh^1^ sqh-AE Gap43RRID: FBal0016066RRID: FBal0298057RRID: FBtp0087760[^12][^13][^14][^15]

Time-lapse imaging {#s4-7}
------------------

Embryos were dechorionated in 50% bleach, mounted ventral side upon a slide coated with 'embryo glue' (double-sided tape soaked in heptane). No. 1.5 coverslips were used as spacers and a No. 1 coverslip was used as a cover to create a chamber for the embryo. The chamber was filled with Halocarbon 27 oil. All imaging occurred at room temperature on a Zeiss LSM 710 confocal microscope with a 40x/1.2 Apochromat water objective ([Figure 3C](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}) or 20X/1.0 Apochromat water objective ([Figure 3A and B](#fig3){ref-type="fig"}). Argon ion and 561 nm diode lasers were used for excitation. The band-pass selected for GFP was \~488--558 nm and for mCherry was \~573--696 nm. All images were acquired using Zen (Zeiss) software. For [Figure 3A](#fig3){ref-type="fig"} and [Figure 3B](#fig3){ref-type="fig"}, embryos of indicated genotype were mounted side-by-side on the same slide and imaged at the same time.

Tissue-cutting {#s4-8}
--------------

Ablations were performed using a Chameleon Ultra II femtosecond pulsed-IR laser (set at 800 nm and 24% intensity) attached to a Zeiss LSM710 with a 40X water immersion objective. To perform ablations, the laser was targeted to a region of interest (8.5 µm line). Image stacks were collected every 1.3 s.

Image analysis {#s4-9}
--------------

Images were processed using Fiji (RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)), and MATLAB (Mathworks, RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)).

### Myosin intensity profile of side-by-side embryos {#s4-9-1}

In Fiji, a Gaussian filter (σ = 1) was applied to all images and a maximum projection was made of all z-slices. A mean intensity profile of the myosin signal along 33 μm of the length of the furrow over a region that extended across the width of both embryos was calculated. The time of the peak myosin intensity for each embryo was determined and the mean intensity profile for each was plotted in [Figure 3A and B](#fig3){ref-type="fig"}.

### Tissue-cutting analysis {#s4-9-2}

In Fiji, for each ablation experiment, a Gaussian filter (σ = 0.7) was applied to all images and a maximum projection was made of both z-slices. Kymographs were taken along the center 4.25 µm of the laser incision. The image was converted to binary mode and a maximum projection was made from these kymographs. Images were imported into MATLAB, the built-in function bwmorph was used to remove outlier points. The distance between the wound edges was calculated for each time point. The displacement was this distance divided by two. The initial recoil velocity was calculated by fitting the displacement to a Kelvin-Voigt model of tissue displacement using the MATLAB build in function lsqcurvefit ([Equation 1](#equ1){ref-type="disp-formula"}).$$x\left( t \right)\  = \ \frac{T}{\varsigma}\left( {1 - e^{\frac{\varsigma t}{\eta}}} \right)$$

Where *t* indicates time, *x(t)* is the displacement of the wound edge, *T* is the tensile force in the tissue prior to the cut, ζ is the stiffness of the spring, and η is the viscous coefficient of the dashpot. Only fits with R-squared values greater than 50% were used in the subsequent calculations of initial recoil velocity. The initial recoil velocity (*v~0~*) is described by the derivative of the displacement at time zero, which is the tension over the viscous coefficient of the dashpot ([Equation 2](#equ2){ref-type="disp-formula"}). The time decay constant (τ) is the viscous coefficient of the dashpot over the stiffness of the spring ([Equation 3](#equ3){ref-type="disp-formula"})$$v_{0} = ~\frac{dx\left( 0 \right)}{dt}~ = ~\frac{T}{\eta}$$$$\tau = \ \frac{\eta}{\zeta}$$

Displacement curves were fit to a power law function ([Equation 4](#equ4){ref-type="disp-formula"}).$$x\left( t \right) = \ \beta x^{\alpha}$$

The exponent (α) of the power law gives a measurement of the viscoelastic properties of the cut tissues ([@bib14]; [@bib16]). Only fits with R-squared values greater than 50% were used.

### Constriction rate analysis {#s4-9-3}

We used custom MATLAB software, EDGE (Embryo Development Geometry Explorer) ([@bib18]) to segment images for quantification of apical area and myosin intensities. Segmented cell membranes were \~1 µm below the myosin signal. Embryos were aligned in time using the mean apical area signals of each embryo and choosing the time when the tissue begins to constrict. The myosin signal was pre-processed to remove cytoplasmic myosin by only using the maximum intensity z-projection for the two highest myosin intensity values that were greater than 2.5 standard deviations above the mean cytoplasmic myosin intensity. A Gaussian filter (σ = 0.5) was applied to this signal. To identify instances of rapid cellular constriction ([Figure 4A](#fig4){ref-type="fig"}), we first smoothed signals for apical area and mean myosin intensity and calculated instantaneous rates for each time point. Instances of rapid myosin intensity increases were identified as instances where the myosin accumulation rate was between one and two standard deviations above the mean rate for all control cells (*RLC-TS*). The constriction rate was calculated at these instances. To identify the amount of time it took the mean apical area of an embryo to decrease to 50% its starting area, we first aligned the mean apical areas of the embryos to each other by matching when the mean area starts to decrease. The initial apical area (A~0~) is defined as the mean area 2 min before this rapid decrease, 0 min in [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"} for all representative embryos. We then determined the amount of time it took for the mean apical area to decrease to 50% of A~0~.

Statistics {#s4-10}
----------

All statistics were performed in MATLAB. *P*-values were calculated using the built-in ranksum function, which performs the Mann-Whitney U test.

Download {#s4-11}
--------

EDGE source code is available at: <https://github.com/mgelbart/embryo-development-geometry-explorer>

Matlab code used for tissue-cutting and constriction rate analyses available at: <https://github.com/clauvasq/myosin-motor>
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Thank you for submitting your article \"*Drosophila* non-muscle myosin II motor activity determines the rate of tissue folding\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, Vasquez et al. address the role that phosphorylation of the *Drosophila* myosin regulatory light chain (RLC) has on myosin-II motor activity, both in vitro and in vivo. By comparing results in these different assays, they are able to address directly the physiological correlation between biochemical activity and tissue phenotypes.

All three reviewers found this paper to be interesting and potentially suitable for *eLife*. They did all raise a number of issues that ought to be addressed, but these are mostly quite detailed and specific, so it is most efficient to list them fully below. The themes that emerged were a) the authors should describe the properties of the mutants in more detail; b) they should provide more detail/analysis of how their results do or don\'t correspond to previous work by others; and c) they need to improve/extend some aspects of their phenotypic analysis.

Overall, the feeling among the reviewers was that this would need little if any extra experimental work, as almost all the issues could be dealt with in the text.

1\) There appear to be some differences in the biochemical properties of *Drosophila* myosin-II (e.g. [Table 3](#tbl3){ref-type="table"} actin sliding velocity) and possibly the K~app~ ([Table 2](#tbl2){ref-type="table"}) compared to mammalian myosins. Are these differences in fact significant?

2\) The actin co-sedimentation assays were difficult to follow in the text ([Figure 1E](#fig1){ref-type="fig"}). Additional explanation of the assay, and which lanes to focus on in the Results, would be helpful.

3\) [Figure 1D](#fig1){ref-type="fig"} shows that there are some differences in the in vitro motility of pAS mutants versus pTS and pTA. Although the results do support Serine-21 as the primary phosphorylation site, it is interesting that the pAS mutant has reduced but significant motility compared to pTS (and more than pTA). This is also seen in [Figure 4A](#fig4){ref-type="fig"}. What role do the authors think this secondary phosphorylation site has on in vivo myosin functions? This could be helpful to add to the Discussion.

4\) In a related comment, the authors show data for RLC-AS cell constriction in [Figure 4A](#fig4){ref-type="fig"} but do not show this mutant in [Figure 4C](#fig4){ref-type="fig"} -- was the RLC-AS mutant tested in tissue invagination? If so, does this mutant have an intermediate effect between RLC-TS and RLC-TA (or is it more similar to RLC-TS)? In other words, is the secondary phosphorylation site truly negligible, or does this mutant show further graded activity of myosin in vivo?

5\) On the last page of the Results, the authors state that \"...the direct comparison of different RLC alleles required normalization for differences in myosin accumulation rates. Therefore, we identified instances with defined rates of apical myosin accumulation and determine the constriction rate at these instances.\" I found the description of this experiment in the Results to be a bit confusing, but it was much clearer in the Materials and methods.

6\) In [Figure 1](#fig1){ref-type="fig"}, there seem to be some minor discrepancies between the actin-activated hydrolysis rates of different variants of RLC ([Figure 1C](#fig1){ref-type="fig"}) and the motility assays ([Figure 1D](#fig1){ref-type="fig"}). These discrepancies don\'t really fit with the idea of an allelic series of motor activities. The ATP hydrolysis rate of RLC-AA, RLC-AE and RLC-AE is about the same and barely above background (panel C). By contrast, there is no motility for RLC-AA and some for RLC-AE and EE (panel D)- why these discrepancies? In fact, the motility of AE and EE is better than pTA, which seems to contradict somewhat the results of the ATP hydrolysis assay.

7\) The characterization of the phosphorylation states of the different RLC variants upon MLCK treatment ([Figure 1---figure supplement 1B-G](#fig1s1){ref-type="fig"}) is only mentioned indirectly. For clarity, it would help if the results from the mass spectrometry would be reported more explicitly in the Results text.

8\) I am not sure I understand what the conclusions are for the actin co-sedimentation assays. Both RLC-TS and RLC-AE HMM fragments behave the same, that is they bind actin in absence of ATP and this complex is disassembled in presence of ATP. Does that mean that they are good actin cross-linkers? Does that explain why, in vivo, TA and AE localize apically as well as TS? In general, there could be more discussion on the crosslinking activities of the RLC variants.

9\) For the electron microscopy in [Figure 2](#fig2){ref-type="fig"}, are the full-length myosin treated with MLCK or only the RLC variants prior to myosin assembly? This was not clear from the Methods or the legend of [Figure 2](#fig2){ref-type="fig"}. If it is the full-length myosin, how sure are the authors that MLCK only phosphorylate RLC in the assay (and not MHC or ELC to stabilise filament formation for example)?

10\) [Figure 4](#fig4){ref-type="fig"}: the authors did not look at the activity of RLC-AA in vivo; why is that? Would they expect AE or EE to have similar characteristics to AA, or in contrast, have higher activity compared to AA? in vitro, on one hand the ATP hydrolysis assays do not really discriminate between AA, AE and EE ([Figure 1](#fig1){ref-type="fig"}---figure -- supplement 2 and [Figure 1C](#fig1){ref-type="fig"}), but on the other hand, AE and EE do much better in the motility assay ([Figure 1D](#fig1){ref-type="fig"}). More generally, do the authors think that the AE and EE variants have any function in vivo (which could be independent of motor activity)? Overall, it would be good to justify more clearly how mutants were selected for testing in vivo.

11\) The authors show that RLC-AE and RLC-EE forms have lower actin-activated ATP hydrolysis rate and lower translocation speed of actin filaments than the phosphorylated forms of the wild-type. The authors also perform actin co-sedimentation assays and find that both wild-type RLC and RLC-AE co-sediment actin at similar levels. RLC-AS and RLC-TA also show lower motor activity than the wild-type, however, the results from the co-sedimentation assay are not shown. Are the non-phosphorylatable forms also able to co-sediment actin? If they are not, would it be possible that these proteins are not binding properly to actin, which would translate in a greater contractile defect?

12\) The authors have extensively characterized different RLC phosphomutants, but there is one widely used phosphomutant, RLC-TE, for which no results are shown. Does this allele also have lower motor activity and lower constriction rate?

13\) The authors find that phosphorylation stabilizes filaments of RLC-AS and RLC-TA. In contrast, addition of ATP to RLC-AA, RLC-AE and RLC-EE, results in depolymerisation of the myosin filaments. At what extent does this occur? If the stabilization of filaments by Myosin phosphorylation is similar for both RLC-AS and RLC-TA, does this mean that the formation of Myosin filaments is not dependent on the phosphorylation site?

14\) The authors show that there are no significant differences in Myosin fluorescence intensity levels in the ventral furrow of embryos with the different Myosin forms. However, other groups have shown that the phosphomimetic form has increased levels at cell junctions (Kasza et al., 2014, Munjal et al., 2015) or increased Myosin pulse amplitude at the medioapical cortex of germband cells (Munjal et al., 2015). In the images shown here ([Figure 3A, B](#fig3){ref-type="fig"}), it seems that the fluorescence levels are saturated in the case of RLC-TA and RLC-AE. The authors could compare images with lower intensity levels. Also, the RLC-AE embryo seems to be at a different stage than the others (the cells at the left of the ventral furrow look very much stretched). Because the authors are measuring the fluorescence intensity levels from maximum intensity projections (of how many slices?), I wonder whether changes in the apico-basal localization of Myosin could be interfering with the fluorescence intensity measurement. Showing the fluorescence intensity per cell at the apical cortex could support their observations.

15\) The authors find that the initial recoil velocity after ablation is reduced in RLC-TA and RLC-AE. To show that the mechanical properties do not change, they do a power-law fit and find no differences between the phosphomutants and the wild-type. However, the maximal displacement looks different between RLC-TA and RLC-AE, with RLC-TA showing a similar maximal displacement to the wild-type. This would suggest that the stiffness could be changing in the RLC-AE. The authors could look at the time decay constant, which represents the ratio of viscosity to stiffness, and also analyse whether there are significant differences in the maximal displacement. This would shed light into whether the mechanical properties of the cells and tissue are changing in the phosphomutants, since this could also be an explanation of the lower cell and tissue constriction rate.

16\) The authors conclude that Myosin motor activity determines the rate of cell and tissue constriction. However, the RLC-AS and RLC-TA have very different Actin-activated ATPase activity and the constriction rates are very similar ([Figure 4B](#fig4){ref-type="fig"}), suggesting that the in vitro behaviour does not completely determine their in vivo activity. What is the rate of tissue invagination in RLC-AS mutants? Previously, the authors have shown that RLC-AE embryos do complete tissue invagination ([Figure 3](#fig3){ref-type="fig"} in Vasquez et al., 2014), so it would be good to quantify the rate of tissue invagination, and to have an idea of the variability between embryos of the same genotype.

17\) The authors conclude that RLC-AE and RLC-EE are not good models for phosphorylated myosin. Suprisingly, the alleles sqhEE and sqhDD (which would behave very similar to the sqhEE, as mentioned by the authors) have been shown to produce excessive cell contraction (Escudero et al., 2007; Aldaz et al., 2013), and to increase cell intercalation (Kasza et al., 2014). These results suggest that there is an activity of Myosin, which is indeed enhanced in these mutants.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"*Drosophila* non-muscle myosin II motor activity determines the rate of tissue folding\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Marianne Bronner (Senior editor), a Reviewing editor, and three reviewers.

The reviewers all agree that the manuscript has been much improved, but before finally and formally accepting it, I\'d appreciate it if you could consider the final few issues below. I will be happy to accept your judgement on the final decisions, but the reviewers did feel that these points might further improve an interesting and important paper.

1\) It was felt to be useful to go ahead and add your response to point \#10 to the text; this would give further context to the mutants shown in vivo.

2\) More generally, it was noted that for some of the issues, you have responded in the rebuttal but not in the text. Will you look through these and consider bringing some of these points into the text to help the non-specialist reader. The reviewers feel that your paper successfully bridges several gaps in our knowledge of in vitro and in vivo systems, and as such will interest a broad audience, from biochemists to developmental biologists, so any effort to improve the accessibility of the manuscript would be appreciated.

As a specific example of this, the Introduction of the paper (third paragraph) poses the problem that crosslinking activity of myosin has been implicated in contractile activity independently of motor activity, but this is not really reexamined in light of your data in the Discussion (there is only a rather vague sentence: \"In the future it will be important to determine whether other properties of myosin, like actin crosslinking, serve other roles during tissue morphogenesis\"). Could you consider adding a section in the Discussion commenting on the cross-linking activities of myosin wild-type and mutant? (For example, see response to point 6: We included the in vitro motility assay in this work to demonstrate that the so-called \"phosphomimetic\" mutants RLC-AA, RLC-AE, and RLC-EE are clearly not mimicking phosphorylation, but can still bind F-actin. This is important because it suggests that these mutants can function as a cross-linker, but translocate actin more slowly when compared with the phosphorylated and unphosphorylated RLC-TS.)

Finally, regarding the laser ablation results, one of the reviewers still has a question that I\'d encourage you to consider and decide whether it would be worth addressing in the text. You find that the initial recoil velocity (tension/viscosity) is decreased in both RLC-TA and RLC-AE mutants when compared to the wild-type, while the time decay constant (viscosity/stiffness) remains unchanged, supporting the idea that tension is lower in both these mutants. However, the maximal displacement (tension/stiffness) of RLC-TA is similar to the wild-type and the maximal displacement of RLC-AE is lower than the wild-type. How do you interpret this result?

10.7554/eLife.20828.015

Author response

*All three reviewers found this paper to be interesting and potentially suitable for eLife. They did all raise a number of issues that ought to be addressed, but these are mostly quite detailed and specific, so it is most efficient to list them fully below. The themes that emerged were a) the authors should describe the properties of the mutants in more detail; b) they should provide more detail/analysis of how their results do or don\'t correspond to previous work by others; and c) they need to improve/extend some aspects of their phenotypic analysis.*

*Overall, the feeling among the reviewers was that this would need little if any extra experimental work, as almost all the issues could be dealt with in the text.*

*1) There appear to be some differences in the biochemical properties of Drosophila myosin-II (e.g. [Table 3](#tbl3){ref-type="table"} actin sliding velocity) and possibly the K~app~ ([Table 2](#tbl2){ref-type="table"}) compared to mammalian myosins. Are these differences in fact significant?*

There were some differences in the ionic strength and the actin concentrations of the various studies, which affect the K~app~, (which is an estimation of the affinity of myosin for actin in the presence of ATP). Differences in the ionic strength have less effect on the k~cat~. k~cat~ is probably more physiologically significant given that the actin concentration in cells is likely to be high. With regards to the in vitro motility assay, there are no published values for full length myosin IIB and myosin IIC. The values for myosin IIA came from a study from the Sellers lab in 1997 using tissue purified platelet myosin, which we now know is essentially pure myosin IIA. Although the buffer conditions of the current study and the Cuda et al. study are slightly different, it is clear that *Drosophila* myosin II is moving actin filaments faster than full length mammalian myosin IIA.

*2) The actin co-sedimentation assays were difficult to follow in the text ([Figure 1E](#fig1){ref-type="fig"}). Additional explanation of the assay, and which lanes to focus on in the Results, would be helpful.*

We have added the text below to the Results and also added lane numbers to the figures.

"To determine if the RLC-AE mutant drastically changes the myosin kinetic pathway, we performed an actin co-sedimentation assay to determine whether the mutant myosin binds to actin in a nucleotide-dependent manner. \[...\] The RLC-AA mutant does mimic known functions of unphosphorylated RLC-TS in that it does not move actin in the in vitro motility assay, but does tether actin to the surface."

*3) [Figure 1D](#fig1){ref-type="fig"} shows that there are some differences in the in vitro motility of pAS mutants versus pTS and pTA. Although the results do support Serine-21 as the primary phosphorylation site, it is interesting that the pAS mutant has reduced but significant motility compared to pTS (and more than pTA). This is also seen in [Figure 4A](#fig4){ref-type="fig"}. What role do the authors think this secondary phosphorylation site has on in vivo myosin functions? This could be helpful to add to the Discussion.*

The conditions of the in vitro motility assay phosphorylation reaction should result in only phosphorylation of Serine-21. In addition, Umemoto et al. JBC, 1989 showed that the velocity of di-phosphorylation of smooth muscle myosin at Threonine-18 and Serine-19 on actin was the same as that of myosin phosphorylated only at Serine-19, i.e. additional phosphorylation of the Threonine did not further increase velocity in contrast to its effects on ATPase activity where it does increase this rate. Thus, the difference in the motility rates of [Figure 1D](#fig1){ref-type="fig"} shown for pTS and pAS are likely due to the presence of the Alanine at residue 20. Please also note that the rate limiting step in the kinetic cycle for ATPase activity is likely to be phosphate release from an actomyosin:ADP-Pi complex, whereas the limiting step for in vitromotility is likely to be detachment of myosin from A.M which is essentially controlled by the rate of ADP release from actin-myosin-ADP. This is because the rate of ATP binding and subsequent dissociation of the actin:myosin complex is very fast. Thus, the differences seen in the effect of mutations on the in vitro motility and ATPase assays are not surprising.

*4) In a related comment, the authors show data for RLC-AS cell constriction in [Figure 4A](#fig4){ref-type="fig"} but do not show this mutant in [Figure 4C](#fig4){ref-type="fig"} -- was the RLC-AS mutant tested in tissue invagination? If so, does this mutant have an intermediate effect between RLC-TS and RLC-TA (or is it more similar to RLC-TS)? In other words, is the secondary phosphorylation site truly negligible, or does this mutant show further graded activity of myosin in vivo?*

We added a new panel of images that show the RLC-AS mutant invagination behavior in [Figure 4C](#fig4){ref-type="fig"}. We also added a new supplemental figure, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, that shows the mean apical area constriction of representative embryos (and averaged multiple embryos) over the time period analyzed in [Figure 4A](#fig4){ref-type="fig"}. Based on the data shown in [Figures 4A, 4C](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} we conclude that the RLC-AS mutant has less of an effect than the RLC-TA mutant. These results demonstrate that the Serine-21 site is the most important phosphorylation site in vivo, and further show that the effects of these mutants on biochemical activity are correlated with their in vivo function.

We added the following: "The *RLC-AE* mutant, which had the greatest defect in motor activity, exhibited the slowest tissue folding behavior, with minimal folding occurring even 9 minutes after myosin first appeared ([Figure 4C](#fig4){ref-type="fig"}). \[...\] Furthermore, the amount of time it takes the mean apical area to decrease to 50% of the starting apical area recapitulates the previously observed pattern: the *RLC-AE* mutanttakes longest time (10.4 minutes) to reach 50% of the initial mean apical area, while the *RLC-AS* and *RLC-TA* mutants take an intermediate amounts of time (7.0 minutes and 7.4 minutes, respectively) relative to the wild-type *RLC-TS* (6.8 minutes) ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"})."

*5) On the last page of the Results, the authors state that \"...the direct comparison of different RLC alleles required normalization for differences in myosin accumulation rates. Therefore, we identified instances with defined rates of apical myosin accumulation and determine the constriction rate at these instances.\" I found the description of this experiment in the Results to be a bit confusing, but it was much clearer in the Materials and methods.*

The reviewer made a good point and we have reworded this part accordingly:

"To identify instances of rapid cellular constriction, we first smoothed signals for apical area and mean myosin intensity and calculated instantaneous rates for each time point. To normalize for differences in myosin accumulate rates, we identified time of rapid myosin intensity increase and selected time periods where myosin accumulated at a given rate (i.e. one to two standard deviations above the mean rate for *RLC-TS* cells). We calculated and compared constriction rates at these instances."

*6) In [Figure 1](#fig1){ref-type="fig"}, there seem to be some minor discrepancies between the actin-activated hydrolysis rates of different variants of RLC ([Figure 1C](#fig1){ref-type="fig"}) and the motility assays ([Figure 1D](#fig1){ref-type="fig"}). These discrepancies don\'t really fit with the idea of an allelic series of motor activities. The ATP hydrolysis rate of RLC-AA, RLC-AE and RLC-AE is about the same and barely above background (panel C). By contrast, there is no motility for RLC-AA and some for RLC-AE and EE (panel D)- why these discrepancies? In fact, the motility of AE and EE is better than pTA, which seems to contradict somewhat the results of the ATP hydrolysis assay.*

As the reviewer points out, there are some differences in relative activity levels between RLC mutants when comparing the ATPase and in vitromotility assays. This is likely because they are rate limited by different kinetic steps of myosin's enzymatic cycle. The rate limiting step in the kinetic cycle for ATPase activity is likely to be phosphate release from the actomyosin:ADP-Pi complex. In contrast, the limiting step for the in vitro motility is likely to be detachment of myosin from actin:myosin which in turn is controlled by the rate of ADP release from actin:myosin:ADP since the rate of ATP binding and subsequent dissociation of the actin:myosin complex is very fast. Thus, the differences seen in the effect of mutations on the in vitro motility and ATPase assays are not surprising. Moreover, ADP release from myosin-II and other myosins is sensitive to the amount of load on the motor (Kovacs et al., *PNAS*, 2007; Laakso et al., Science, 2008). Because the in vivo load on the motor is unknown, how the velocity from the motility assay relates to in vivo motility is unknown. We included the in vitromotility assay in this work to demonstrate that the so-called "phosphomimetic" mutants RLC-AA, RLC-AE, and RLC-EE are clearly not mimicking phosphorylation, but can still bind F-actin. This is important because it suggests that these mutants can function as a cross-linker, but translocate actin more slowly when compared with the phosphorylated and unphosphorylated RLC-TS.

*7) The characterization of the phosphorylation states of the different RLC variants upon MLCK treatment ([Figure 1---figure supplement 1B-G](#fig1s1){ref-type="fig"}) is only mentioned indirectly. For clarity, it would help if the results from the mass spectrometry would be reported more explicitly in the Results text.*

We agree with the reviewer, we now directly mention these results in the Results section:

"We tested the ability of MLCK to phosphorylate RLC mutants. We found that RLC-AS and RLC-TA can each only be phosphorylated by MLCK at one site, Serine-21 and Threonine-20 ([Figure 1---figure supplement 1C, D](#fig1s1){ref-type="fig"}). \[...\] This set of mutants also allowed us to individually determine the importance of phosphorylation of Threonine-20 and Serine-21 on myosin motor function."

*8) I am not sure I understand what the conclusions are for the actin co-sedimentation assays. Both RLC-TS and RLC-AE HMM fragments behave the same, that is they bind actin in absence of ATP and this complex is disassembled in presence of ATP. Does that mean that they are good actin cross-linkers? Does that explain why, in vivo, TA and AE localize apically as well as TS? In general, there could be more discussion on the crosslinking activities of the RLC variants.*

These experiments were included to show that while the RLC-AE clearly has a major effect on the actin-activated ATPase activity and in vitro motility ([Figure 1C, D](#fig1){ref-type="fig"}), it does not totally wreck the myosin kinetic cycle. All myosin II isoforms have the property that in the absence of ATP, myosin binds strongly to actin, whereas the presence of the nucleotide dramatically weakens the affinity for actin. The actin co-sedimentation assays directly show that RLC-TS and RLC-AE both bind and pellet with F-actin (lanes 4 and 10, respectively) to similar extents in the absence of ATP. In addition, the assay shows the responsiveness of both RLC-TS and RLC-AE to nucleotide state; we observe that myosin largely remains in the supernatant (lanes 5 and 11) and in the presence of ATP, which is what is expected for a proper cross-bridge cycle. The small fraction of myosin from both samples that sediments with actin is consistent with the weakening of the actomyosin affinity in the presence of ATP. We have rewritten this part of the Results to make our conclusions more clear.

*9) For the electron microscopy in [Figure 2](#fig2){ref-type="fig"}, are the full-length myosin treated with MLCK or only the RLC variants prior to myosin assembly? This was not clear from the Methods or the legend of [Figure 2](#fig2){ref-type="fig"}. If it is the full-length myosin, how sure are the authors that MLCK only phosphorylate RLC in the assay (and not MHC or ELC to stabilise filament formation for example)?*

MLCK is an incredibly specific enzyme for the phosphorylation of RLC. In 36 years of studying regulation of various myosin II isoforms by MLCK in the Sellers lab, we have never observed any indication of myosin heavy chain phosphorylation even in experiments where the phosphorylation of the secondary Threonine site was explored which required addition of 50-100 times as much kinase as was needed to phosphorylated the Serine residue only. We are not aware of any other substrate ever being described for MLCK. Furthermore, RLC-AA, RLC-AE, and RLC-EE were all unresponsive to MLCK treatment demonstrating that Threonine-20 and Serine-21 are the important residues for regulation ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

*10) [Figure 4](#fig4){ref-type="fig"}: the authors did not look at the activity of RLC-AA in vivo; why is that? Would they expect AE or EE to have similar characteristics to AA, or in contrast, have higher activity compared to AA? in vitro, on one hand the ATP hydrolysis assays do not really discriminate between AA, AE and EE ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [Figure 1C](#fig1){ref-type="fig"}), but on the other hand, AE and EE do much better in the motility assay ([Figure 1D](#fig1){ref-type="fig"}). More generally, do the authors think that the AE and EE variants have any function in vivo (which could be independent of motor activity)? Overall, it would be good to justify more clearly how mutants were selected for testing in vivo.*

The in vivoeffects of *RLC-AA* have already been reported (Vasquez et al., JCB,2014). These mutants have defects in cellularization, which precedes tissue folding (Vasquez et al., JCB,2014; Xue and Sokac, JCB, 2016). It is likely that the RLC-AA mutant is not able to oligomerize at all, in contrast to RLC-AE and RLC-EE, which form aggregates with heavy chain in vivo (Vasquez et al.,JCB, 2014).

*11) The authors show that RLC-AE and RLC-EE forms have lower actin-activated ATP hydrolysis rate and lower translocation speed of actin filaments than the phosphorylated forms of the wild-type. The authors also perform actin co-sedimentation assays and find that both wild-type RLC and RLC-AE co-sediment actin at similar levels. RLC-AS and RLC-TA also show lower motor activity than the wild-type, however, the results from the co-sedimentation assay are not shown. Are the non-phosphorylatable forms also able to co-sediment actin? If they are not, would it be possible that these proteins are not binding properly to actin, which would translate in a greater contractile defect?*

We did not explore the actin-cosedimentation of the all the mutant forms of RLC, but the RLC-AE is a non-phosphorylatable form. We explored the requirement for phosphorylation in the in vitro motility assay. In numerous other studies from the Sellers lab we have shown that even though unphosphorylated smooth and nonmuscle myosins do not move actin filaments, they do tether actin filaments to the coverslip surface. This is almost certainly a result of the weak-actin binding affinity that was demonstrated in co-sedimentation assays described in [Figure 1E](#fig1){ref-type="fig"}. Based on this we would expect all of the mutants to show low levels of co-sedimentation with actin in the presence of ATP and to be able to function as a weak actin tether if they form filaments inside the cell.

*12) The authors have extensively characterized different RLC phosphomutants, but there is one widely used phosphomutant, RLC-TE, for which no results are shown. Does this allele also have lower motor activity and lower constriction rate?*

The most commonly used phosphomutant is the RLC-EE mutant. In the examples given by the referees (point 17) where the phosphomimetic mutant results in excessive contraction (Escudero et al., Dev Cell, 2007; Aldaz et al., Nat Commun, 2013; Kasza et al., PNAS, 2014), the data mostly involves the *RLC-EE* or *RLC-DD* mutants. There is only one panel of one figure that shows a result involving the *RLC-TE* mutant. Therefore, we disagree that the *RLC-TE* mutant is widely used.

We already have addressed the function of the primary and secondary phosphorylation sites with Alanine mutants, where the interpretation is most clear. In addition, we tested the ability of glutamic acid to mimic phosphorylation, in mutants that did not contain phosphorylatable residues (*RLC-AE* and *RLC-EE*), where the interpretation is again most clear. Therefore, we respectfully disagree that biochemically characterizing the *RLC-TE* would change our conclusions or add to the manuscript.

*13) The authors find that phosphorylation stabilizes filaments of RLC-AS and RLC-TA. In contrast, addition of ATP to RLC-AA, RLC-AE and RLC-EE, results in depolymerisation of the myosin filaments. At what extent does this occur? If the stabilization of filaments by Myosin phosphorylation is similar for both RLC-AS and RLC-TA, does this mean that the formation of Myosin filaments is not dependent on the phosphorylation site?*

The reviewer is correct that the interpretation of [Figure 2](#fig2){ref-type="fig"} is that phosphorylation of RLC-TA and RLC-AS stabilizes myosin filaments. Thus, filament formation requires phosphorylation, but is not dependent on the site phosphorylated.

*14) The authors show that there are no significant differences in Myosin fluorescence intensity levels in the ventral furrow of embryos with the different Myosin forms. However, other groups have shown that the phosphomimetic form has increased levels at cell junctions (Kasza et al., 2014, Munjal et al., 2015) or increased Myosin pulse amplitude at the medioapical cortex of germband cells (Munjal et al., 2015). In the images shown here ([Figure 3A, B](#fig3){ref-type="fig"}), it seems that the fluorescence levels are saturated in the case of RLC-TA and RLC-AE. The authors could compare images with lower intensity levels. Also, the RLC-AE embryo seems to be at a different stage than the others (the cells at the left of the ventral furrow look very much stretched). Because the authors are measuring the fluorescence intensity levels from maximum intensity projections (of how many slices?), I wonder whether changes in the apico-basal localization of Myosin could be interfering with the fluorescence intensity measurement. Showing the fluorescence intensity per cell at the apical cortex could support their observations.*

None of the images we used to compare intensity values are saturated. In addition, the embryos were imaged side-by-side so that a direct intensity comparison could be made. The past studies that the reviewer mentioned (Kasza et al., PNAS, 2014; Munjal et al., Nature,2015) did not image embryos under the exact same imaging conditions, making it difficult to directly compare fluorescence intensity measurement. Nevertheless, we have done the experiment that the reviewer suggested: We have measure fluorescence intensity per cell at the apical cortex and it is the same when comparing *RLC-TS, RLC-TA*, and *RLC-AE* (Vasquez et al., JCB, 2014, Figure 5 and Figure supplement 4). We now provide the result where mutant and wild-type embryos are imaged under identical conditions and present that here as the most rigorous proof that the levels are not changed.

*15) The authors find that the initial recoil velocity after ablation is reduced in RLC-TA and RLC-AE. To show that the mechanical properties do not change, they do a power-law fit and find no differences between the phosphomutants and the wild-type. However, the maximal displacement looks different between RLC-TA and RLC-AE, with RLC-TA showing a similar maximal displacement to the wild-type. This would suggest that the stiffness could be changing in the RLC-AE. The authors could look at the time decay constant, which represents the ratio of viscosity to stiffness, and also analyse whether there are significant differences in the maximal displacement. This would shed light into whether the mechanical properties of the cells and tissue are changing in the phosphomutants, since this could also be an explanation of the lower cell and tissue constriction rate.*

The reviewer is correct in that there is a difference in the maximal displacement and also the initial recoil velocity. We did as the reviewer suggested and analyzed the time decay constant for fits to the Kelvin-Voigt model. We now include this analysis in [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}, which indicated there was not a significant difference between the *RLC-AE* and wild-type *RLC-TS* recoil curves. Together with the power law exponents we determined, our analysis suggests that the lower recoil velocity is due to lower tension and not a different stiffness of the tissue.

We state: "Differences between the power law exponents of *RLC-TS, RLC-TA*, and *RLC-AE* embryos were not significant ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). \[...\] In agreement with power law exponents, differences between time decay constants of RLC-TS, RLC-TA, and RLC-AE embryos were not significant ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).

*16) The authors conclude that Myosin motor activity determines the rate of cell and tissue constriction. However, the RLC-AS and RLC-TA have very different Actin-activated ATPase activity and the constriction rates are very similar ([Figure 4B](#fig4){ref-type="fig"}), suggesting that the in vitro behaviour does not completely determine their in vivo activity. What is the rate of tissue invagination in RLC-AS mutants? Previously, the authors have shown that RLC-AE embryos do complete tissue invagination ([Figure 3](#fig3){ref-type="fig"} in Vasquez et al., 2014), so it would be good to quantify the rate of tissue invagination, and to have an idea of the variability between embryos of the same genotype.*

To illustrate the invagination of the different mutants, we have: 1) Added images of the *RLC-AS* mutant embryos to [Figure 4C](#fig4){ref-type="fig"}, and 2) Provided quantification of the invagination/contraction for all mutants in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. The *RLC-AS* mutant embryos constrict only slightly less well than wild-type embryos and do not disrupt tissue folding as much as the *RLC-TA* mutant. Again, the effects we see on tissue folding are entirely consistent with the defects in ATPase activity observed in vitro. Note that we present data from 2-3 embryos per genotype, but have looked at many more embryos. What we present is representative of the folding behavior we have observed in many embryos per genotype.

*17) The authors conclude that RLC-AE and RLC-EE are not good models for phosphorylated myosin. Suprisingly, the alleles sqhEE and sqhDD (which would behave very similar to the sqhEE, as mentioned by the authors) have been shown to produce excessive cell contraction (Escudero et al., 2007; Aldaz et al., 2013), and to increase cell intercalation (Kasza et al., 2014). These results suggest that there is an activity of Myosin, which is indeed enhanced in these mutants.*

Some of the work the reviewer mentions involves overexpressing the *sqhEE* or *sqhDD* in a wild-type background (Escudero et al., Dev Cell, 2007; Aldaz et al., Nat Commun,2013). It is clear that the *sqhEE* mutant exhibits cortical localization in the absence of an upstream kinase (Vasquez et al., JCB, 2014; Kasza et al., PNAS, 2014; Munjal et al., Nature,2015). Functional myosin is an oligomer (i.e. bipolar filament consisting of 12 molecules in *Drosophila*). In addition, myosin molecules can form mixed filaments (i.e. hetero-oligomers) with other myosins (Beach et al., Curr Biol, 2014). Thus, overexpression of *sqhEE* is likely to form mixed filaments with phosphorylated wild-type *sqh* (for evidence for this, see Vasquez et al., JCB, 2014)and result in more wild-type myosins being polymerized into bipolar filaments. Because *sqhEE* is incapable of contraction without Rho Kinase (Vasquez et al., JCB, 2014; Kasza et al., PNAS,2014) it is the wild-type phosphorylatable *sqh* that is most likely promoting the excessive contractile activity.

In Kasza et al. the authors expressed *sqhEE* in a hypomorphic *sqh* background. There is still 10% levels of wild-type *sqh.* Indeed, making germline clones using a *sqh* null allele does not result in embryos (Vasquez et al. JCB, 2014), consistent with it lacking function. Kasza et al. did see excessive shortening of cell edges, but the subsequent elongation was defective (Kasza et al., PNAS, 2014). This elongation is driven by cortical actomyosin contractions in the apex (Collinet et al., NCB, 2015; Yu and Fernandez-Gonzalez, *eLife*, 2016). Thus, there is a germband elongation defect for *sqhEE* and it is likely due to a defect in myosin motor activity.

We state: "Past work has suggested that *RLC-EE* can promote contraction (Aldaz et al., 2013; Escudero et al., 2007; Kasza et al., 2014). \[...\] Importantly, *RLC-EE* is incapable of contraction without ROCK (Kasza et al., 2014; Munjal et al., 2015; Vasquez et al., 2014), suggesting that the wild-type phosphorylatable *RLC* is responsible for excessive cellular contraction in these experiments."

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*The reviewers all agree that the manuscript has been much improved, but before finally and formally accepting it, I\'d appreciate it if you could consider the final few issues below. I will be happy to accept your judgement on the final decisions, but the reviewers did feel that these points might further improve an interesting and important paper.*

*1) It was felt to be useful to go ahead and add your response to point \#10 to the text; this would give further context to the mutants shown in vivo.*

Thanks for the suggestion, we added the following statement in the manuscript at the beginning of the "Apical constriction rate scales with the measured in vitro myosin motor activity" section: "The in vivo effects of RLC-AA have already been reported (Vasquez et al., JCB, 2014). These mutants have defects in cellularization, which precedes tissue folding (Vasquez et al., 2014; Xue and Sokac, 2016). It is likely that the RLC-AA mutant is not able to oligomerize at all, in contrast to RLC-AE and RLC-EE, which form aggregates with heavy chain in vivo (Vasquez et al., 2014)."

*2) More generally, it was noted that for some of the issues, you have responded in the rebuttal but not in the text. Will you look through these and consider bringing some of these points into the text to help the non-specialist reader. The reviewers feel that your paper successfully bridges several gaps in our knowledge of in vitro and in vivo systems, and as such will interest a broad audience, from biochemists to developmental biologists, so any effort to improve the accessibility of the manuscript would be appreciated.*

*As a specific example of this, the Introduction of the paper (third paragraph) poses the problem that crosslinking activity of myosin has been implicated in contractile activity independently of motor activity, but this is not really reexamined in light of your data in the Discussion (there is only a rather vague sentence: \"In the future it will be important to determine whether other properties of myosin, like actin crosslinking, serve other roles during tissue morphogenesis\"). Could you consider adding a section in the Discussion commenting on the cross-linking activities of myosin wild-type and mutant? (For example, see response to point 6: We included the in vitro motility assay in this work to demonstrate that the so-called \"phosphomimetic\" mutants RLC-AA, RLC-AE, and RLC-EE are clearly not mimicking phosphorylation, but can still bind F-actin. This is important because it suggests that these mutants can function as a cross-linker, but translocate actin more slowly when compared with the phosphorylated and unphosphorylated RLC-TS.)*

We have gone through our rebuttal and think that all relevant points addressed in the rebuttal are in the main text of the manuscript. We added one point in the Discussion regarding actin crosslinking: "Importantly, our in vitro motility assay results demonstrate that the phosphomutants RLC-AA, RLC-AE, and RLC-EE are clearly not mimicking phosphorylation, but can still bind F-actin. This is important because it suggests that these mutants can function as cross-linkers, if they oligomerize, but translocate actin more slowly when compared with the phosphorylated and unphosphorylated RLC-TS."

*Finally, regarding the laser ablation results, one of the reviewers still has a question that I\'d encourage you to consider and decide whether it would be worth addressing in the text. You find that the initial recoil velocity (tension/viscosity) is decreased in both RLC-TA and RLC-AE mutants when compared to the wild-type, while the time decay constant (viscosity/stiffness) remains unchanged, supporting the idea that tension is lower in both these mutants. However, the maximal displacement (tension/stiffness) of RLC-TA is similar to the wild-type and the maximal displacement of RLC-AE is lower than the wild-type. How do you interpret this result?*

The reduction in maximal recoil displacement for RLC-AE is consistent with this mutant having the greatest reduction in tissue tension. We have added the following sentence to indicate our interpretation, "RLC-AE exhibited a reduced maximal recoil distance ([Figure 3D](#fig3){ref-type="fig"}), which is also consistent with decreased tissue tension".
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